ClinicalTrials.gg
RecruitingNCT07862010GI001-01Updated Oct 7, 2026

Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia

An Early Phase 1 interventional study of GI001 in B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia, sponsored by Hematology department of the 920th hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Hematology department of the 920th hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Nov 2025, registered Sep 2026).
  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Planned enrollment
203rd of 273
18 · median 30
Started
2025
with 40 others
Phase 1
124 of 283
57 open now
Primary completion
2027-11
later than 95 of 145 live
Registered
282nd of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 203rd largest by planned enrollment of the 273 interventional ones that give a count, is one of 41 that started in 2025, is one of 124 in phase 1, reaches primary completion later than 95 of the 145 other live ones, and was the 282nd registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multi-cohort, investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL) and B-cell Acute Lymphoblastic Leukemia (R/R B-ALL).

GI001 is an exploratory, in vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting the CD19 antigen. Unlike traditional CAR-T cell therapies that require extensive in vitro cell manufacturing, GI001 is administered directly to the patient via intravenous infusion, aiming to generate CAR-T cells directly within the patient's body.

The study consists of two main phases:

  • Dose-Escalation Phase: This phase will evaluate four ascending dose levels to assess safety, identify any Dose-Limiting Toxicities (DLTs), determine the Maximum Tolerated Dose (MTD), and establish the Recommended Dose for Expansion (RDE). It utilizes an accelerated titration design for the initial doses, followed by a standard "3+3" dose-escalation design.
  • Dose-Expansion Phase : Once the RDE is identified, additional patients will be enrolled to further evaluate the safety, clinical efficacy, pharmacokinetics, and pharmacodynamics of GI001 at the selected dose(s).

The primary focus of the study is to continuously monitor adverse events and evaluate the overall safety profile. Secondary objectives include assessing clinical response rates (such as Objective Response Rate and Complete Response Rate), survival outcomes, and the expansion levels of CAR-T cells in the peripheral blood.

Read the detailed description

This is an open-label, multi-cohort, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with R/R B-NHL and R/R B-ALL. The study is divided into a Dose-Escalation Phase and a potential Dose-Expansion Phase.

Dose-Escalation Phase

  • The dose-escalation phase evaluates four dose levels: 1 x 10E8 TU, 4 x 10E8 TU, 1.2 x 10E9 TU, and 2.4 x 10E9 TU.
  • Cohorts 1 and 2 utilize an accelerated titration design, initially enrolling 1 subject per cohort.
  • If a Dose-Limiting Toxicity (DLT), ‭$\ge$‬ Grade 2 non-hematologic toxicity (occurring ‭$\ge$‬ 2 times), or evidence of excessive CAR-T expansion occurs, the cohort switches to a standard "3+3" design.
  • Cohorts 3 and 4 follow a standard "3+3" escalation rule based on the occurrence of DLTs during a 28-day observation period.
  • A Safety Review Committee (SRC) will evaluate the safety data to determine dose escalation, Maximum Tolerated Dose (MTD), and Recommended Dose for Expansion (RDE).

Dose-Expansion Phase

  • If applicable, 1 to 2 dose levels from the escalation phase will be selected as the RDE.
  • Approximately 12 to 18 additional subjects will be enrolled to further evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

Study Procedures

  • Screening and Baseline: Eligible subjects undergo screening (Day -30 to Day -3) and baseline assessments (Day -2 to Day -1) to confirm eligibility and establish baseline status.
  • Treatment Administration: Subjects may receive premedication (e.g., promethazine or diphenhydramine) 15 to 30 minutes prior to infusion. GI001 is administered via a single intravenous infusion (lasting up to 2 hours) on Day 0.
  • Observation Period: Subjects will be hospitalized for at least 14 days post-infusion for close safety monitoring. The DLT observation period spans 28 days (Day 1 to Day 28).
  • Follow-up: Short-term follow-up continues until Day 90, followed by efficacy and safety evaluations every 3 months until Month 12, and then every 6 months until Month 24.
  • Long-Term Follow-up: After the 2-year period, subjects enter a 15-year long-term follow-up phase to monitor survival, delayed toxicities, and replication-competent lentivirus (RCL) risk.
03

Conditions studied

  • B-Cell Non-Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia

Keywords

  • GI001
  • CD19
  • CAR-T
  • In vivo CAR-T
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Age 18 to 75 years, inclusive.

  • 2. Diagnosis of CD19-positive (R/R) B-cell non-Hodgkin lymphoma (B-NHL) or R/R B-cell acute lymphoblastic leukemia (B-ALL):
  • 2.1 CD19-positive R/R B-NHL meeting the following:
  • Histopathologic diagnosis of indolent NHL (iNHL), including but not limited to follicular lymphoma (FL) and marginal zone lymphoma (MZL), or small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL); or aggressive B-cell lymphoma, including but not limited to diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and T-cell/histiocyte-rich large B-cell lymphoma (TCRBCL).
  • Refractory disease defined as: (a) best response of progressive disease (PD) to standard therapy, or stable disease (SD) after at least 4 cycles of first-line therapy with SD duration not exceeding 6 months after the last treatment; or (b) no response to second-line or later therapy, including best response of PD to the most recent therapy, or SD after at least 2 cycles of the most recent therapy with SD duration not exceeding 6 months after the last treatment; or (c) disease progression within 12 months after hematopoietic stem cell transplantation (ASCT) or -confirmed relapse, or no remission or relapse (SD or PD) after salvage therapy following ASCT.
  • Relapse defined as PD after achieving a response (partial response [PR] or complete response [CR]) to adequate prior therapy.
  • Note: participants must have received adequate prior therapy; participants with CD20-positive disease must have failed or relapsed after anti-CD20 monoclonal antibody therapy.
  • 2.2 CD19-positive R/R B-ALL meeting the following:
  • Relapse defined as: (a) hematologic relapse: reappearance of blasts (>=5%) in peripheral blood or bone marrow, or extramedullary disease, in a participant who had achieved CR; or (b) molecular relapse: reappearance of measurable residual disease (MRD) positivity after hematologic CR (HCR) and CR MRD negativity, with an increase in MRD level of >=1 log between two positive specimens.
  • Refractory disease defined as: (a) failure to achieve CR after at least 2 cycles of standard chemotherapy, or late relapse (>=12 months) after CR with failure to achieve CR after at least 1 additional cycle; or (b) relapse after hematopoietic stem cell transplantation, or failure to achieve remission with the last therapy in participants receiving salvage therapy after HSCT; or (c) failure to achieve CR or relapse after at least 2 tyrosine kinase inhibitors (TKIs) (participants with TKI-resistance mutations such as T315I/A, V299L, F317L/V/I/C, G250E, Y253H, E255K/V, or F359V/C/I are not required to have received at least 2 TKIs), or intolerance to or for TKIs, in Philadelphia chromosome-positive (Ph+) B-ALL.
  • 2.3 Participants who are not eligible for stem cell transplantation, or whose medical records document refusal of other available therapies, may also be enrolled.
  • 3. CD19 expression positivity confirmed by immunohistochemistry (IHC) or flow cytometry (FACS) on tumor specimen, bone marrow, or peripheral blood at screening.
  • 4. per Lugano 2014 criteria for B-NHL participants (nodal lesion LDi > 1.5 cm, extranodal lesion LDi > 1.0 cm); bone marrow blasts and immature lymphocytes >=5% for B-ALL participants at screening.
  • 5. performance status 0 to 2.
  • 6. Expected survival >=12 weeks.
  • 7. Adequate organ function meeting all of the following laboratory results before enrollment:
  • Hematology: bone marrow reserve for R/R B-NHL participants must meet: (ANC) > 0.5 x 10\^9/L (no short-acting G-CSF within 7 days and no long-acting G-CSF within 14 days before testing); absolute lymphocyte count (ALC) >= 0.5 x 10\^9/L; count >= 30 x 10\^9/L (no platelet transfusion within 7 days before testing); >= 80 g/L (no red blood cell transfusion within 7 days before testing; recombinant erythropoietin permitted). All participants (B-NHL and B-ALL) require absolute CD3+ T cell count >= 150/uL.
  • Hepatic: (ALT) and aspartate aminotransferase (AST) \<= 3 x (ULN); total serum \<= 2 x ULN.
  • Renal: (CrCl) >= 60 mL/min (Cockcroft-Gault formula).
  • Coagulation: fibrinogen >= 1.0 g/L; \<= 1.5 x ULN; prothrombin time (PT) \<= 1.5 x ULN.
  • Cardiac: (LVEF) >= 55%; oxygen saturation > 91%.
  • 8. Therapeutic-dose must be discontinued 72 hours before GI001 infusion (physiologic replacement-dose steroids are permitted).
  • 9. CNS disease prophylaxis (e.g., intrathecal methotrexate) must be discontinued 1 week before GI001 infusion.
  • 10. Participants and their partners agree to use effective barrier or pharmacologic (excluding calendar/rhythm methods) from the time of through 1 year after GI001 administration.
  • 11. Written informed consent approved by the ethics committee must be obtained before initiating any screening procedures.

Exclusion criteria

Exclusion Criteria:

1. Prior antitumor therapy as follows (except agents proven to enhance CAR-T cell efficacy or not to affect CAR-T cells, after an appropriate ):

  • Cytotoxic chemotherapy within 2 weeks before dosing.
  • Small molecule targeted therapy within 2 weeks before dosing.
  • Antibody therapy within 3 weeks before dosing.
  • Pegylated asparaginase within 4 weeks before dosing.
  • therapy within 4 weeks before dosing or requirement for long-term immunosuppression.
  • Radiotherapy within 4 weeks before dosing.
  • Bendamustine within 6 months before dosing.
  • Prior treatment with any gene therapy product, including CAR-T therapy (except participants with no in vivo CAR-T, normal T cell count and function, and CD19-positive tumor).
  • Prior treatment with any anti-CD19/anti-CD3 therapy or any other anti-CD19 therapy (except participants with normal T cell count and function and CD19-positive tumor).
  • Other drugs or other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) before dosing.
  • 2. Other within 2 years before screening, excluding adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical prostatectomy, ductal carcinoma in situ of the breast after radical surgery, and papillary thyroid carcinoma after radical treatment.
  • 3. History of solid organ transplantation.
  • 4. Use of immunomodulatory agents within 2 weeks before dosing, or likely use during the study, including but not limited to thalidomide, lenalidomide, and pomalidomide.
  • 5. Requirement for long-term therapeutic-dose (defined as prednisone or equivalent > 15 mg/day); physiologic replacement, topical, and inhaled use are permitted.
  • 6. Prior or current CNS involvement or suspected CNS involvement: leukemia or lymphoma cells detected in cerebrospinal fluid (CSF); or imaging findings of mass, thickening, or enhancement in brain parenchyma, meninges, cranial nerves, or spinal cord supporting a diagnosis of CNS involvement; or neurologic signs or symptoms with abnormal CSF findings suggestive of CNS involvement.
  • 7. Hypertension not controllable with medication.
  • 8. Severe cardiac disease, including but not limited to: myocardial infarction within 6 months before screening; coronary artery bypass grafting or coronary stent placement within 6 months before screening; unstable angina; congestive heart failure ( class >= III); severe arrhythmia; history of severe non-ischemic cardiomyopathy.
  • 9. Unstable systemic disease as judged by the investigator, including but not limited to severe hepatic, renal, or metabolic disease requiring medication.
  • 10. Uncontrolled active bacterial, fungal, viral, or other infection, or infection requiring intravenous anti-infective therapy (uncontrolled infection defined as persistent infection-related signs or symptoms without improvement after appropriate anti-infective therapy).
  • 11. Stroke, seizure, or other CNS disease unsuitable for this study within 6 months before screening; uncontrolled psychiatric disorder; or any medical or psychiatric history that in the investigator's judgment may increase the risk of study participation or dosing, or may interfere with study results.
  • 12. History of deep vein thrombosis or pulmonary embolism within 6 months before screening.
  • 13. within 6 weeks before screening.
  • 14. Major surgery within 2 weeks before screening, or planned surgery within 2 weeks after dosing (excluding surgery under local anesthesia).
  • 15. Pregnant or breastfeeding women, or women planning pregnancy during or after treatment.
  • 16. Non-hematologic toxicity from prior therapy not resolved to baseline or \<= grade 2 (excluding alopecia, fatigue, and peripheral neuropathy).
  • 17. Prior treatment with a therapeutic pseudotyped with vesicular stomatitis virus glycoprotein (VSVG) or Nipah virus.
  • 18. Positive surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with hepatitis B virus DNA (HBV-DNA) above the lower limit of detection; positive virus (HCV) antibody with HCV-RNA above the lower limit of detection; positive (HIV) antibody; or positive syphilis serology.
  • 19. Isolated extramedullary relapse of B-ALL.
  • 20. to the investigational drug or its , or to tocilizumab.
  • 21. Primary immunodeficiency.
  • 22. Planned hematopoietic stem cell transplantation within 28 days after GI001 infusion.
  • 23. Any other condition that in the investigator's judgment makes the participant unsuitable for enrollment.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Dose Level -1: GI001 3.5x10^8 TU

    Single intravenous infusion of GI001, an in vivo CD19-targeted CAR-T therapy, at dose level -1 (3.5x10\^8 TU; TU = transducing units). Premedication with intramuscular promethazine 25 mg or diphenhydramine 20 mg is recommended 15-30 minutes before infusion. Infusion duration does not exceed 2 hours. No lymphodepleting conditioning is specified in the protocol. This dose level is explored only if a safety signal is observed at the starting dose.

    Biological: GI001

  • Experimental
    Dose Level 1: GI001 7.0x10^8 TU

    Single intravenous infusion of GI001, an in vivo CD19-targeted CAR-T therapy, at dose level 1 (7.0x10\^8 TU), the starting dose. Premedication with intramuscular promethazine 25 mg or diphenhydramine 20 mg is recommended 15-30 minutes before infusion. Infusion duration does not exceed 2 hours. No lymphodepleting conditioning is specified in the protocol. Enrollment follows a 3+3 dose-escalation design: the first participant is observed for at least 2 weeks before the next participants are enrolled.

    Biological: GI001

  • Experimental
    Dose Level 2: GI001 1.0x10^9 TU

    Single intravenous infusion of GI001, an in vivo CD19-targeted CAR-T therapy, at dose level 2 (1.0x10\^9 TU). Premedication with intramuscular promethazine 25 mg or diphenhydramine 20 mg is recommended 15-30 minutes before infusion. Infusion duration does not exceed 2 hours. No lymphodepleting conditioning is specified in the protocol. Escalation to this dose level occurs if no DLT is observed at the previous dose level.

    Biological: GI001

Interventions

  • BiologicalGI001

    GI001 is an in vivo CD19-targeted CAR-T therapy. It is a lentiviral vector-based product using a third-generation self-inactivating lentiviral vector system with a five-plasmid packaging design. GI001 is administered by intravenous injection and delivers the CD19 CAR gene directly into the patient, reprogramming the patient's own T cells in situ to express CD19 CAR without ex vivo cell manufacturing. No lymphodepleting conditioning is required, and a single injection is given. GI001 is supplied as a colorless to slightly opaque liquid, 1 mL per vial, stored at -70 +/- 10 degrees C. Infusion duration does not exceed 2 hours. Dose levels evaluated in this study are 3.5x10\^8 TU, 7.0x10\^8 TU and 1.0x10\^9 TU (TU = transducing units). Recommended premedication is intramuscular promethazine 25 mg or diphenhydramine 20 mg given 15-30 minutes before infusion. Dose modification is not permitted (a +/-20% dose range is acceptable).

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    Incidence, severity, seriousness, and relationship to GI001 of treatment-emergent adverse events and serious adverse events. Severity graded per NCI CTCAE v6.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) graded per ASTCT 2019 consensus criteria; immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) graded per ASTCT 2023 criteria.

    Time frame: From baseline through 2 years after GI001 administration

  2. Change from baseline in body temperature

    Change from baseline in body temperature, measured in degrees Celsius, at each scheduled post-dose assessment.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  3. Percentage of participants with dose-limiting toxicities (DLTs)

    Percentage of participants in the DLT analysis set who experience at least one protocol-defined DLT within 28 days after GI001 administration. The analysis set includes participants who complete DLT assessment or experience a DLT during the assessment period. DLTs are treatment-related toxicities defined in Protocol Section 4.1.4, including qualifying cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infusion-related hypersensitivity, non-hematologic toxicities, neutropenia with severe infection, thrombocytopenia with qualifying bleeding, and grade 5 toxicity. Protocol-specified severity thresholds, recovery criteria, and exclusions apply. The number and percentage of participants with DLTs will be summarized.

    Time frame: From GI001 administration through 28 days after administration

  4. Maximum tolerated dose (MTD)

    The highest GI001 dose level, expressed in transducing units (TU), at which no more than 1 of 6 evaluable participants experiences a protocol-defined dose-limiting toxicity (DLT) during the 28-day observation period after administration. If only 3 participants have been enrolled at the candidate MTD, 3 additional participants are enrolled for confirmation. The MTD is determined from the dose-escalation cohort data.

    Time frame: From GI001 administration through 28 days after administration for each participant in the dose-escalation phase

  5. Recommended dose for expansion (RDE)

    GI001 dose level(s), expressed in transducing units (TU), selected for expansion by the Safety Review Committee based on available safety, tolerability, preliminary efficacy, pharmacokinetic, pharmacodynamic, and immunogenicity data from the dose-escalation phase.

    Time frame: From GI001 administration through 90 days after administration for each participant in the dose-escalation phase

  6. Change from baseline in systolic blood pressure

    Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg), at each scheduled post-dose assessment.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  7. Change from baseline in pulse rate

    Change from baseline in pulse rate, measured in beats per minute, at each scheduled post-dose assessment.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  8. Change from baseline in respiratory rate

    Change from baseline in respiratory rate, measured in breaths per minute, at each scheduled post-dose assessment.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  9. Change from baseline in ECOG performance status score

    Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status score at each scheduled post-dose assessment. Scores range from 0 (fully active) to 5 (death), with higher scores indicating worse performance status.

    Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration

  10. Change from baseline in heart rate measured by 12-lead ECG

    Change from baseline in heart rate, measured in beats per minute by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.

    Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration

  11. Change from baseline in PR interval measured by 12-lead ECG

    Change from baseline in PR interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.

    Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration

  12. Change from baseline in R-R interval measured by 12-lead ECG

    Change from baseline in R-R interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.

    Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration

  13. Change from baseline in diastolic blood pressure

    Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg), at each scheduled post-dose assessment.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  14. Change from baseline in QRS duration measured by 12-lead ECG

    Change from baseline in QRS duration, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.

    Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration

  15. Change from baseline in QT interval measured by 12-lead ECG

    Change from baseline in QT interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.

    Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration

  16. Change from baseline in QTcF interval measured by 12-lead ECG

    Change from baseline in QT interval corrected for heart rate using the Fridericia formula (QTcF), measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. QTcF = QT / (RR in seconds)\^(1/3). After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.

    Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration

  17. Number of participants by change from baseline in physical examination findings

    Physical examination findings are classified as normal or abnormal by the investigator. The number of participants in each baseline-to-post-dose category (normal to normal, normal to abnormal, abnormal to normal, or abnormal to abnormal) will be summarized by examined body system and scheduled visit. Examinations cover the head, eyes, ears, nose, throat, neck, heart, chest including lungs, abdomen, extremities, skin, lymph nodes, nervous system, and general condition. Post-dose examinations may focus on clinically indicated organs and systems, as specified in the protocol.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  18. Number of participants by change from baseline in overall 12-lead ECG assessment

    The overall 12-lead electrocardiogram (ECG) assessment is classified as normal or abnormal by the investigator. The number of participants in each baseline-to-post-dose category (normal to normal, normal to abnormal, abnormal to normal, or abnormal to abnormal) will be summarized at each scheduled post-dose assessment. This outcome describes the overall ECG interpretation; quantitative ECG parameters are reported separately.

    Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration

  19. Change from baseline in red blood cell count

    Change from baseline in red blood cell count, measured in 10\^12/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  20. Change from baseline in hemoglobin concentration

    Change from baseline in hemoglobin concentration, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  21. Change from baseline in hematocrit

    Change from baseline in hematocrit, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  22. Change from baseline in white blood cell count

    Change from baseline in white blood cell count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  23. Change from baseline in platelet count

    Change from baseline in platelet count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  24. Change from baseline in absolute neutrophil count

    Change from baseline in absolute neutrophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  25. Change from baseline in absolute lymphocyte count

    Change from baseline in absolute lymphocyte count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  26. Change from baseline in absolute monocyte count

    Change from baseline in absolute monocyte count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  27. Change from baseline in absolute eosinophil count

    Change from baseline in absolute eosinophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  28. Change from baseline in absolute basophil count

    Change from baseline in absolute basophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  29. Change from baseline in neutrophil percentage

    Change from baseline in neutrophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  30. Change from baseline in lymphocyte percentage

    Change from baseline in lymphocyte percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  31. Change from baseline in monocyte percentage

    Change from baseline in monocyte percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  32. Change from baseline in eosinophil percentage

    Change from baseline in eosinophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  33. Change from baseline in basophil percentage

    Change from baseline in basophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  34. Change from baseline in alanine aminotransferase (ALT)

    Change from baseline in alanine aminotransferase (ALT), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  35. Change from baseline in aspartate aminotransferase (AST)

    Change from baseline in aspartate aminotransferase (AST), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  36. Change from baseline in gamma-glutamyl transferase (GGT)

    Change from baseline in gamma-glutamyl transferase (GGT), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  37. Change from baseline in alkaline phosphatase (ALP)

    Change from baseline in alkaline phosphatase (ALP), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  38. Change from baseline in lactate dehydrogenase (LDH)

    Change from baseline in lactate dehydrogenase (LDH), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  39. Change from baseline in creatine kinase (CK)

    Change from baseline in creatine kinase (CK), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  40. Change from baseline in creatine kinase-MB (CK-MB) activity

    Change from baseline in creatine kinase-MB (CK-MB) activity, measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  41. Change from baseline in total bilirubin

    Change from baseline in total bilirubin, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  42. Change from baseline in direct bilirubin

    Change from baseline in direct bilirubin, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  43. Change from baseline in creatinine

    Change from baseline in creatinine, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  44. Change from baseline in uric acid

    Change from baseline in uric acid, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  45. Change from baseline in glucose

    Change from baseline in glucose, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  46. Change from baseline in urea

    Change from baseline in urea, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  47. Change from baseline in potassium

    Change from baseline in potassium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  48. Change from baseline in sodium

    Change from baseline in sodium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  49. Change from baseline in chloride

    Change from baseline in chloride, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  50. Change from baseline in inorganic phosphorus

    Change from baseline in inorganic phosphorus, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  51. Change from baseline in total protein

    Change from baseline in total protein, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  52. Change from baseline in albumin

    Change from baseline in albumin, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  53. Change from baseline in globulin

    Change from baseline in globulin, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  54. Change from baseline in albumin-to-globulin ratio

    Change from baseline in albumin-to-globulin ratio, measured in unitless, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  55. Change from baseline in prothrombin time (PT)

    Change from baseline in prothrombin time (PT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  56. Change from baseline in activated partial thromboplastin time (APTT)

    Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  57. Change from baseline in thrombin time (TT)

    Change from baseline in thrombin time (TT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  58. Change from baseline in fibrinogen

    Change from baseline in fibrinogen, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  59. Change from baseline in international normalized ratio (INR)

    Change from baseline in international normalized ratio (INR), measured in unitless, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  60. Change from baseline in urine pH

    Change from baseline in urine pH, measured in pH units, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  61. Change from baseline in urine white blood cell count

    Change from baseline in urine white blood cell count, measured in cells/microliter, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  62. Change from baseline in urine red blood cell count

    Change from baseline in urine red blood cell count, measured in cells/microliter, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  63. Change from baseline in magnesium

    Change from baseline in magnesium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  64. Change from baseline in troponin concentration measured by chemiluminescence immunoassay

    Change from baseline in troponin concentration measured by chemiluminescence immunoassay, measured in ng/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  65. Change from baseline in D-dimer

    Change from baseline in D-dimer, measured in mg/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  66. Number of participants by change from baseline in urine protein category

    Number of participants in each baseline-to-post-dose category of urine protein at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  67. Number of participants by change from baseline in urine glucose category

    Number of participants in each baseline-to-post-dose category of urine glucose at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  68. Number of participants by change from baseline in urine ketones category

    Number of participants in each baseline-to-post-dose category of urine ketones at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  69. Number of participants by change from baseline in urine urobilinogen category

    Number of participants in each baseline-to-post-dose category of urine urobilinogen at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

  70. Number of participants by change from baseline in urine leukocyte esterase category

    Number of participants in each baseline-to-post-dose category of urine leukocyte esterase at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.

    Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration

07

Study locations

1 of 1 sites recruiting
  • The 920th Hospital of Joint Logistics Support Force, PLA
    Yunnan, Kunming, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 117 non-industry phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Oct 7, 2026
StartActual
Nov 28, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862010
Lead sponsor
Hematology department of the 920th hospital
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Nov 28, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Sanbing Wang Principal Investigator
Contact
wangsanbin2022@126.com
0871-64788278

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion